A RIPK1 inhibitor advanced into a Phase I human clinical trial for the treatment of ALS had to be terminated due to long-term dose-limiting toxity of the compound under investigation unrelated to the target.9 Recently, Sanofi and Denali advanced another RIPK1 inhibitor (SAR443820) into a Phase II multi-center, randomized, double-blind, placebo-controlled trial, named HIMALAYA trial, for the treatment of ALS (ClinicalTrials.gov ID: NCT05237284). Here, RIPK1 is linked to amyotrophic lateral sclerosis.